Måndag 1 September | 17:20:36 Europe / Stockholm

Kalender

Est. tid*
2025-07-28 - Kvartalsrapport 2025-Q2
2025-05-07 - X-dag ordinarie utdelning EL 3.95 EUR
2025-04-30 - Extra Bolagsstämma
2025-04-30 - Årsstämma
2025-02-12 - Bokslutskommuniké 2024
2024-07-25 - Kvartalsrapport 2024-Q2
2024-05-03 - X-dag ordinarie utdelning EL 3.95 EUR
2024-04-30 - Extra Bolagsstämma
2024-04-30 - Årsstämma
2024-02-14 - Bokslutskommuniké 2023
2023-07-26 - Kvartalsrapport 2023-Q2
2023-05-22 - X-dag ordinarie utdelning EL 3.23 EUR
2023-05-17 - Extra Bolagsstämma
2023-05-17 - Årsstämma
2023-03-10 - Bokslutskommuniké 2022
2022-07-29 - Kvartalsrapport 2022-Q2
2022-05-30 - X-dag ordinarie utdelning EL 2.51 EUR
2022-05-25 - Extra Bolagsstämma
2022-05-25 - Årsstämma
2022-03-11 - Bokslutskommuniké 2021
2021-07-30 - Kvartalsrapport 2021-Q2
2021-05-28 - X-dag halvårsutdelning EL 1.08
2021-05-21 - Extra Bolagsstämma
2021-05-21 - Årsstämma
2021-03-12 - Bokslutskommuniké 2020
2020-12-23 - X-dag bonusutdelning EL 1.15
2020-06-25 - Extra Bolagsstämma
2020-06-25 - Årsstämma
2019-10-30 - Kvartalsrapport 2019-Q3
2025-07-21 08:00:00

EssilorLuxottica to acquire PUcore’s division dedicated to the development, manufacturing and sale of ophthalmic lens materials 

The acquisition will enhance the Group’s R&D and production capabilities for the manufacturing of innovative high index, thinner and lighter ophthalmic lenses, and ensure long term sustainable sourcing

Paris, France (21 July 2025) – EssilorLuxottica announces today it has signed an agreement with the South Korean company PUcore for the acquisition of all its assets and entities involved in the development, manufacturing and sale of monomers used in the production of high index ophthalmic lenses.

The activities acquired by EssilorLuxottica include a R&D unit, a materials production facility and a sales office in the Republic of Korea. As part of the transaction, the Group will also acquire an intellectual property portfolio in relation to the formulations of products and production processes.

“We are happy to welcome PUcore’s optical division and its talented teams into our Group. In line with our commitment to elevating standards in the research, development and manufacturing of ophthalmic lenses, this addition will allow us to widen our portfolio of patents, technologies and know-how and extend our expertise upstream in the value chain. By continuing to improve the production and formulation of high index monomers, we will raise the bar for the performance and sustainability of the processes and supplies used across the entire ophthalmic industry,” commented Francesco Milleri, Chairman and Chief Executive Officer, and Paul du Saillant, Deputy Chief Executive Officer at EssilorLuxottica.

The transaction is expected to close by the end of 2025 pending regulatory approvals and other customary closing conditions.